Evolving Treatment Strategies in Early HER2+ Breast Cancer

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal antibodies likely do not cross an intact blood brain barrier which is often why patients develop brain metastases

EP: 1.Treatment Selection and Sequencing in Third Line Settings and Beyond

EP: 2.Understanding Janet's Journey: Navigating HER2+ Metastatic Breast Cancer & Treatment Options

EP: 3.Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA

EP: 4.Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection

EP: 5.Managing Oral Treatments and Patient Support Strategies in HER2+ mBC: Multidisciplinary Perspectives

EP: 6.Barbara's Story: Navigating HER2+ MBC with Brain Metastases & Tucatinib-Based Treatment in the Second-Line Setting

Now Viewing

EP: 7.Evolving Treatment Strategies in Early HER2+ Breast Cancer

EP: 8.Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS

EP: 9.Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC

Video content above is prompted by the following:

• Summarize and provide insight on the second patient case.
• Please discuss the data surrounding efficacy and treating HER-2 positive brain metastases.

Recent Videos